No Long-Term Safety Data: CDSCO Panel Denies Novo Nordisk's proposal to amend warning statement of Semaglutide Dr. Divya Colin16 March 2025 5:15 PM ISTNew Delhi: Citing that there is no real world long-term safety data for Novo Nordisk's antidiabetic drug Semaglutide tablets (3 mg, 7 mg, 14 mg), the...
Anti-obesity drugs benefit kidney transplant recipients with type 2 diabetes: Study Dr. Kamal Kant Kohli15 March 2025 9:00 AM ISTKidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and...
Taking semaglutide before bariatric surgery does not improve weight loss or safety, reveals research Dr. Kamal Kant Kohli14 March 2025 8:15 PM ISTMass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before having weight loss surgery,...
CagriSema demonstrates superior weight loss in adults with obesity, type 2 diabetes in REDEFINE 2 trial: Novo Nordisk Ruchika Sharma14 March 2025 2:00 PM ISTDenmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial, Novo...
Hetero Labs Gets CDSCO Panel Nod To study Semaglutide Injection for Type 2 Diabetes Mellitus Dr. Divya Colin10 March 2025 6:00 PM ISTNew Delhi: Hetero Labs has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization...
Alkem Laboratories Gets CDSCO Panel Nod To study Semaglutide tablet for Type 2 Diabetes Mellitus Dr. Divya Colin9 March 2025 6:00 PM ISTNew Delhi: Alkem Laboratories has got the go ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
GLP-1 drug shows little benefit for people with Parkinson's disease: Study Dr. Kamal Kant Kohli2 March 2025 9:30 PM ISTThe GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL...
CDSCO Panel approves Zydus Lifesciences to study Semaglutide Injection Dr. Divya Colin28 Feb 2025 6:00 PM ISTNew Delhi: Accepting the bioequivalence study report for Type 2 Diabetes Mellitus, the Subject Expert Committee (SEC) functional under the Central...
Alkem Laboratories Gets CDSCO Panel Nod To Study Semaglutide solution for injection Dr. Divya Colin25 Feb 2025 6:00 PM ISTNew Delhi: Citing that the retinal examination (fundoscopy) shall be done periodically, the Subject Expert Committee (SEC) functional under the...
Dr Reddy's Laboratories Gets CDSCO Panel Nod To Study Semaglutide in Type 2 Diabetes Mellitus Dr. Divya Colin20 Feb 2025 6:00 PM ISTNew Delhi: Responding to the proposal presented by Dr. Reddy's Laboratories, the Subject Expert Committee (SEC) functional under the Central Drug...
Retinal examination be done at each visit: CDSCO Panel tells Alkem Lab on Semaglutide Injection Phase III CT study Dr. Divya Colin15 Feb 2025 6:00 PM ISTNew Delhi: Considering the bioequivalence study report of Semaglutide Injection 2 mg presented by the drug major Alkem Laboratories, the Subject...
Neuro-ophthalmologists concerned over Ophthalmic complications in patients on antidiabetic GLP-1 medications: JAMA Dr. Kamal Kant Kohli14 Feb 2025 8:15 PM IST A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a direct causal link...
